JERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec
Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today
announces that two posters in support of the Company's Phase 3
clinical development program for the Accordion Pill™
Carbidopa/Levodopa (AP-CD/LD), will be presented at the
upcoming International Congress of Parkinson's and Movement
Disorder Society (MDS 2019) being held from September
22-26, 2019 in Nice, France.
"We are pleased to have these posters at this key Parkinson's
disease (PD) medical meeting discussing our ACCORDANCE Phase 3
clinical development program for the AP-CD/LD in advanced PD
patients. We believe these posters will enhance the understanding
of and highlight the continued potential for this late-stage
program among an audience of scientists, clinicians and industry
experts who specialize in Parkinson's disease management,"
stated Jeffrey A. Meckler, Vice Chairman and Chief Executive
Officer of Intec Pharma. "This is particularly important as we
seek to partner AP-CD/LD for continued late-stage clinical
development and commercialization in PD patients."
The following posters will be presented during MDS 2019:
Title:
|
Patients Experiencing
Motor Fluctuations with Parkinson's Disease: Participant
Characteristics in
the ACCORDANCE Phase 3 Efficacy and Safety Trial
of
Accordion Pill®-Carbidopa/Levodopa
|
Poster
Session:
|
Parkinsonisms and
Parkinson-Plus
|
Poster
Number:
|
952
|
Presentation
Date:
|
Tuesday, September
24, 2019
|
Presentation
time:
|
1:45 – 3:15 pm (local
time)
|
Presenter:
|
R. Michael Gendreau,
M.D., Ph.D.,
Chief Medical Officer
of Intec Pharma
|
Title:
|
Pharmacokinetics of
Accordion Pill®-Carbidopa/Levodopa Following
Multiple
Doses in Patients
with Parkinson's Disease
|
Poster
Session:
|
Parkinsonisms and
Parkinson-Plus
|
Poster
Number:
|
1006
|
Presentation
Date:
|
Tuesday, September
24, 2019
|
Presentation
time:
|
1:45 – 3:15 pm (local
time)
|
Presenter:
|
Jeffery A.
Meckler,
Vice Chairman and
Chief Executive Officer of Intec Pharma
|
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is in late-stage Phase 3 development for the
treatment of Parkinson's disease symptoms in advanced Parkinson's
disease patients, and AP-cannabinoids, an Accordion Pill to deliver
either or both of the primary cannabinoids contained in Cannabis
sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for
various pain indications. In addition, the Company has a
feasibility agreement for the development of a custom-designed
Accordion Pill for a proprietary compound with Novartis
Pharmaceuticals and a research collaboration with Merck &
Co.
For more information, visit www.intecpharma.com. Intec Pharma
routinely posts information that may be important to investors in
the Investor Relations section of its website.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward looking statements about our
expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as
"believe", "expect", "intend", "plan", "may", "should", "could",
"might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to, the following: our limited operating
history and history of operating losses, our ability to continue as
a going concern, our ability to obtain additional financing, our
ability to successfully operate our business or execute our
business plan, the timing and cost of our clinical trials, the
completion and receiving favorable results in our clinical trials,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to protect and maintain our
intellectual property and licensing arrangements, our ability to
develop, manufacture and commercialize our product candidates, the
risk of product liability claims, the availability of
reimbursement, and the influence of extensive and costly government
regulation. More detailed information about the risks and
uncertainties affecting us is contained under the heading "Risk
Factors" included in our most recent Annual Report on Form 10-K
filed with the SEC on February 27, 2019, and in
other filings that we have made and may make with
the Securities and Exchange Commission in the future.
Intec Pharma Investor Contact:
Anne Marie
Fields
VP-Corporate Communications & Investor Relations
646-200-8808
amf@intec-us.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-to-present-two-posters-at-international-congress-of-parkinsons-and-movement-disorder-society-300918484.html
SOURCE Intec Pharma Ltd.